Premium
Changes of the Serum Amikacin (AMK) Level in Patients with Serious Acute Renal Failure Treated by Continuous Arteriovenous Hemofiltration (CAVH)
Author(s) -
Takagi N.,
Oda H.,
Tokita Y.,
Yabana M.,
Toya Y.,
Abe Y.,
Ueda S.,
Minamisawa K.,
Yamada Y.,
Ishigami T.,
Gotoh T.,
Takeda K.,
Ishii M.
Publication year - 1989
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1989.tb02869.x
Subject(s) - medicine , amikacin , blood urea nitrogen , hemofiltration , urine , acute kidney injury , urology , anesthesia , creatinine , antibiotics , chemistry , hemodialysis , biochemistry
This study clarified changes in the serum amikacin (AMK) levels in the blood of 5 patients (4 men and 1 woman; average age 59.2 ± 5.9 years) with serious acute renal failure treated by continuous arteriovenous hemofiltration (CAVH). The following principal results were obtained. (A) The average remaining rate of AMK in the blood after 6 h was 60.8 ± 5.3% and 50.4 ± 5.3% after 12 h. The average half‐life period (t 1/2 ß) of AMK in the blood during CAVH was 18.3 ± 3.4 h. (B) The remaining rate of AMK in the blood after 12 h correlated significantly with the blood urea nitrogen (BUN) level (r = 0.71, p < 0.05) and with the volume of urine excreted per day (r =‐0.71, p < 0.05). (C) The average lowest AMK concentration after 24 h for a continuous 17‐day period was 3.3 μ/ml. These results suggest that the administration of 100 mg of AMK once a day is useful and safe for patients with serious acute renal failure treated by CAVH and that it will not accumulate in the body.